These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 22154408)

  • 1. Literature review and practical aspects on the management of oxaliplatin-associated toxicity.
    Hoff PM; Saad ED; Costa F; Coutinho AK; Caponero R; Prolla G; Gansl RC
    Clin Colorectal Cancer; 2012 Jun; 11(2):93-100. PubMed ID: 22154408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
    Kurniali PC; Luo LG; Weitberg AB
    Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of oxaliplatin-associated neurotoxicity.
    Grothey A
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
    Leonard GD; Wright MA; Quinn MG; Fioravanti S; Harold N; Schuler B; Thomas RR; Grem JL
    BMC Cancer; 2005 Sep; 5():116. PubMed ID: 16168057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer.
    Grothey A
    Oncology; 2010; 79(5-6):389-99. PubMed ID: 21447970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.
    Park SB; Lin CS; Krishnan AV; Goldstein D; Friedlander ML; Kiernan MC
    Brain; 2009 Oct; 132(Pt 10):2712-23. PubMed ID: 19745023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin-related neurotoxicity: how and why?
    Pasetto LM; D'Andrea MR; Rossi E; Monfardini S
    Crit Rev Oncol Hematol; 2006 Aug; 59(2):159-68. PubMed ID: 16806962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity reactions to oxaliplatin in two asian patients.
    Ng CV
    Ann Pharmacother; 2005 Jun; 39(6):1114-8. PubMed ID: 15886290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.
    Argyriou AA; Cavaletti G; Briani C; Velasco R; Bruna J; Campagnolo M; Alberti P; Bergamo F; Cortinovis D; Cazzaniga M; Santos C; Papadimitriou K; Kalofonos HP
    Cancer; 2013 Jan; 119(2):438-44. PubMed ID: 22786764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
    Wang WS; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Chiou TJ; Liu JH; Yen CC; Chen PM
    Oncologist; 2007 Mar; 12(3):312-9. PubMed ID: 17405895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.
    Park SB; Goldstein D; Lin CS; Krishnan AV; Friedlander ML; Kiernan MC
    J Clin Oncol; 2009 Mar; 27(8):1243-9. PubMed ID: 19164207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
    Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
    Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up.
    Pietrangeli A; Leandri M; Terzoli E; Jandolo B; Garufi C
    Eur Neurol; 2006; 56(1):13-6. PubMed ID: 16825773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
    Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
    Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Milla P; Airoldi M; Weber G; Drescher A; Jaehde U; Cattel L
    Anticancer Drugs; 2009 Jun; 20(5):396-402. PubMed ID: 19287306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
    Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumour effect.
    Garg MB; Ackland SP
    Cancer Chemother Pharmacol; 2011 Apr; 67(4):963-6. PubMed ID: 20976600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amelioration of oxaliplatin neurotoxicity by drugs in humans and experimental animals: a minireview of recent literature.
    Ali BH
    Basic Clin Pharmacol Toxicol; 2010 Apr; 106(4):272-9. PubMed ID: 20050845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin-associated neuropathy: a review.
    Cersosimo RJ
    Ann Pharmacother; 2005 Jan; 39(1):128-35. PubMed ID: 15590869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.